GPIbα shedding occurs inside thrombi and results in maximal retention of glycocalicin, but intrathrombic GPIbα shedding is regulated differently between humans and mice and is not universally mediated by ADAM17.
Glycocalicin concentration inside human thrombi was approximately 4-fold higher than in initial plasma.
In vitro experiments confirmed glycocalicin accumulation inside thrombi, with 6-fold increases from human platelet-rich plasma and 3-fold increases from murine whole blood.
In vivo containment of glycocalicin inside thrombi following inferior vena cava (IVC) ligation in mice was even more pronounced than in vitro findings.
Inhibition of ADAM17 in human samples reduced glycocalicin concentration inside thrombi by approximately 3-fold compared to thrombi with competent ADAM17.
Inhibition or genetic absence of ADAM17 in mice did not reduce intrathrombic GPIbα shedding, indicating species-specific differences in regulation.
GPIbα proteolysis occurs inside thrombi in a process considered too slow to be crucial in primary hemostasis, suggesting a role in later stages of thrombus biology.
This research suggests that when blood clots form, a fragment of a key platelet surface protein called glycoprotein Ibα (GPIbα) — known as glycocalicin — does not simply disperse into the bloodstream. Instead, glycocalicin becomes strongly trapped inside the clot itself. The researchers found that glycocalicin concentrations inside human blood clots were about four times higher than in the surrounding plasma, and this pattern was confirmed in laboratory experiments with both human and mouse blood as well as in a living mouse model of vein clotting, where concentrations inside clots were up to 16 times higher than in plasma. This means the clot microenvironment becomes highly enriched with this protein fragment during and after clot formation. The study also investigated how glycocalicin gets released from platelets inside the clot. In human samples, blocking the enzyme ADAM17 — which cuts GPIbα from the platelet surface — reduced the amount of glycocalicin inside clots by about three times, confirming ADAM17 as the primary driver of this process in humans. However, when the same enzyme was blocked pharmacologically or removed genetically in mice, it made no difference to glycocalicin levels inside mouse clots. This indicates that in mice, other enzymes or mechanisms compensate for the loss of ADAM17, highlighting an important biological difference between humans and mice. These findings matter for several reasons. They show that GPIbα shedding is an active process happening within clots, not just on circulating platelets, and that the resulting glycocalicin builds up locally rather than entering general circulation. The marked differences between humans and mice also serve as a caution for researchers: results from mouse models of platelet biology may not always translate directly to human biology, particularly when studying receptor shedding mechanisms.
Debaene C, Six K, Vertongen S, De Buck C, Feys H. (2026). Glycocalicin is contained inside the thrombus.. Platelets. https://doi.org/10.1080/09537104.2026.2743143